. Rates of 12-month persistency for anti-inflammatory biologics by diagnosis, comorbidity, and cost-sharing amount.
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Among insured patients, out-of-pocket costs for biologics may be high. Previous research suggests higher cost-sharing for biologics is associated with higher rates of abandonment (failure to pick up a filled prescription at the pharmacy).
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Higher out-of-pocket costs also may affect medication persistency (continuation of the treatment for the prescribed duration).
Route of administration also may affect adherence. Previous studies have reached various conclusions about persistency and adherence for anti-inflammatory biologics administered intravenously versus subcutaneously. [3] [4] [5] To improve understanding of factors related to persistency for biologics, we conducted a study using data from multiple, geographically diverse U.S. health plans.
The study objectives were to:
1. Determine unadjusted rates of 12-month persistency for five commonly-used anti-inflammatory biologic agents 2. Identify cost-sharing level, route of administration and patient characteristics associated with persistency
Background
In this study, high patient cost-sharing amounts were associated with lower rates of medication persistency. Specialty medicines are typically placed in a high cost tier in benefit designs. When undertaking efforts to improve patient adherence to therapy with anti-inflammatory biologics, patient and plan benefit characteristics should be considered.
Conclusions
• Persistency was higher for drugs administered intravenously rather than subcutaneously, which suggests that administration in the medical setting (as opposed to self-administration by the patient) may have a beneficial effect on adherence. This may be an important consideration for benefit design and patient incentives for use of pharmacy versus medical benefits.
• Persistency was lower in patients with comorbidities. This is not unexpected, as comorbidities add to the complexity of a patient's treatment regimen and may contribute to adherence lapses, frustration, and giving up on therapy. 6 • Persistency was lower in those new to therapy. This finding is consistent with previous research.
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• Although the relationship between persistency and cost-sharing was not linear, cost-sharing amounts ≥$300 were associated with lowest persistency. This pattern is consistent with a prior study of specialty drug adherence in new patients.
Limitations
• Results could be confounded by selection bias of patients, physicians or both.
• Out-of-pocket cost measures do not account for copayment assistance programs.
• Clinical factors (e.g., safety, efficacy) were not measured.
Discussion Patients
• 15,834 patients met study criteria ("all patients" group)
• 1414 patients were new to therapy ("new patients" subgroup)
Outcomes
• Twelve-month persistency rates were 70.7% among all patients and 51.5% among new patients.
• Persistency was highest for infliximab (82.3%), followed by adalimumab (66.1%), certolizumab pegol (65.5%), etanercept (65.1%) and tocilizumab (60.6%) (P <.01).
• Higher 12-month persistency was observed for drugs administered intravenously versus subcutaneously (81.2% vs. 65.6%, P <.01).
• Persistency was higher in patients with Crohn's disease/ulcerative colitis than in patients with rheumatoid arthritis or psoriatic conditions (79.1% vs. 67.0% and 61.4%, respectively, P <.01).
• Persistency was higher in patients with no comorbidities than in those with 1 or ≥2 (P <.01).
• Highest persistency was observed for patients with a mean plan cost-sharing amount of $50 to <$100, followed by $0 to<$50, $100 to <$300 and ≥$300 (P <.01). This trend was observed irrespective of intravenous or subcutneous route of administration.
• A multivariate analysis was also conducted, controlling for diagnosis, comorbidity, incident pain, incident health event, new patient and cost-sharing amount. Results were consistent with the bivariate findings. That analysis will be presented elsewhere.
Results
This was a retrospective, observational, cross-sectional study using a proprietary administrative claims database for >30 U.S. commercial health plans (9.2 million members)(Artemetrx, Brentwood TN, USA).
Patients
Inclusion criteria
• commercially insured
• age ≥18 years
• ≥1 claim for an anti-inflammatory biologic in 2012 or 2013
• continuous enrollment from the date of the index claim (first claim for an anti-inflammatory biologic in the database) through 15 months post-index claim
New patients subgroup
• at least 6 months of continuous enrollment prior to the index claim
• no claims for an anti-inflammatory biologic in the 6 months prior to the index claim Anti-Inflammatory Biologics
Outcome Measures 12-Month Persistency 12-month persistency was defined as a treatment length of at least 365 days after the index claim without a therapy gap or switch in therapy.
• A therapy gap was defined as a gap ≥60 days after the drug depletion date with no claim for the same drug.
• Depletion date for pharmacy claims was defined as claim fill date plus days supply. Depletion date for medical claims was based on diagnosis-specific U.S. Food and Drug Administration (FDA)-approved dosing schedules. For infliximab, it was assumed that each medical claim was for a 60-day supply. 3 We determined the percentage of patients with 12-month persistency for individual drugs and all drugs combined. We also calculated persistency rates by diagnosis, number of comorbidities, incident pain, route of administration (subcutaneous versus intravenous), plan cost-sharing amount and new patient status. Pearson's chi-square test was used in the bivariate analyses to determine the association between categorical variables. 
Methods

Definitions
Index claim: The patient's first claim for an anti-inflammatory biologic in the study database.
Indications: Crohn's disease/ulcerative colitis, psoriasis/psoriatic arthritis and rheumatoid arthritis. An indication was considered present if a single claim with a relevant ICD-9 diagnosis code occurred from 90 days prior to 365 days after the initial dispensing.
Comorbidities: Cancer, depression, diabetes mellitus, dyslipidemia, hypertension, ischemic heart disease and musculoskeletal disorders other than rheumatoid arthritis or ankylosing spondylitis.
Incident pain: A new pain diagnosis in the 12 months after the index claim.
Route of administration: Subcutaneously administered drugs included adalimumab, certolizumab pegol and etanercept; intravenously administered drugs included infliximab and tocilizumab.
Plan cost-sharing amount: The average plan cost-sharing amount for all claims in the therapeutic class. Cost-sharing amounts were inclusive of deductibles, co-insurance and copayments.
